Professor Szabo is an internationally recognized expert in the fields of oxidative and nitrosative stress, gaseous transmitters, cell death, cell dysfunction, cardiovascular, and inflammatory mechanisms. In the mid 90's he has pioneered the concept that identified the pathogenetic role of the nuclear enzyme PARP in promoting cell necrosis, and its roles in cardiovascular and inflammatory diseases. His applied research and development work in this area led to novel drug candidates that have progressed into clinical trials. Over the last decade, he has developed a significant track record in the biology of hydrogen sulfide, where he has identified multiple regulatory roles of this mediator in angiogenesis, reperfusion injury and cancer. His background (two Ph.D. degrees in physiology and pharmacology, coupled with his medical background [M.D.]) and his diverse research interests, which range from basic cell death mechanisms to vascular injury, diabetes, shock, heart failure, inflammatory diseases, diabetes and its complications) as well as his dual activities in academia (basic research) and in industry (applied research and drug development) are substantial. His expertise range from the regulation of nitric oxide synthases, through oxidant and antioxidant mechanisms including peroxynitrite, and cellular inflammatory mechanisms and pathways including neuroimmunomodulation, and the bacterial protein flagellin. His background and expertise are internationally recognized in the pathogenesis of circulatory shock, diabetes, myocardial infarction, cardiomyopathy, stroke, neuroinflammation, and diabetic complications. He has published over 500 original research articles has been in the top 10 most cited pharmacologists in the world for the last decade. He was recently listed as one of the top 400 most infuential biomedical scientists in the word. He has been continuously funded by the National Institutes of Health since 1995, and has recieved a cumulative extramural funding of over $15 million. Currently at the Department of Anesthesiology at the University of Texas Medical Branch, Professor Szabo leads a multidisciplinary team of investigators with expertise in molecular biology, cell biology, pharmacology, physiology, pathophysiology, medicinal chemistry and translational science. Professor Szabo has received numerous awards, including the Novartis Award of the British Pharmacological Society and the Dennis Gabor Innovation Award, and the Texas Star Award. He serves or served on the Editorial Board of numerous leading journals, including the British Journal of Pharmacology, the Journal of Pharmacology and Experimental Therapeutics, Shock, and Molecular Medicine. He is an Elected Fellow of the British Pharmacological Society and an Elected Member of the American Society for Clinical Investigation.
r. Prescott conducts health services research to understand and improve the long-term outcomes of acute medical illnesses, drawing on the tools of ‘big data’ analytics and implementation science. Her initial focus is reducing the need for repeated hospitalization after severe sepsis, including an examination of hospital readmissions and healthcare utilization among sepsis survivors, with a goal of helping develop novel clinical interventions to improve recovery and reduce healthcare utilization among this population. • M.D., Ohio State University • M.Sc., Health and Health Care Research, University of Michigan • B.A., Molecular Biology & Biochemistry, Middlebury College
Department of Pediatrics | Faculty of Medicine
Vice-President Medical Affairs | BC Children’s Hospital
Associate Head | Critical Care | Pediatrics
Simon Finfer is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health. He is a practicing critical care physician with an appointment as a Senior Staff Specialist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital, the largest not-for-profit hospital in New South Wales.
Simon is an Professor at the University of New South Wales, and a Clinical Professor at the University of Sydney. He is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. He chairs the Council of the International Sepsis Forum, and is a member (Treasurer) of the Global Sepsis Alliance Executive. Simon is a member of the World Sepsis Day Steering Committee and recently co-chaired the 1st World Sepsis Congress, a two-day free online congress that attracted 14,000 registrants.
His postgraduate qualifications include Fellowships of the Royal Colleges of Physicians, the Royal College of Anaesthetists and the College of Intensive Care Medicine. He was elected to the ANZICS Honour Roll in 2011 and in 2012 he was awarded an honorary doctorate (Doctor of Medicine) by The Friedrich-Schiller University in Germany, an honour awarded once every 10 years. He is a Fellow of the Australian Academy of Health and Medical Sciences.
Simon’s major research interest is the design and conduct of large scale randomised controlled trials in critical care. Simon is active in forging major international research collaborations that have conducted large scale clinical trials and epidemiological research to improve the treatment of critically ill and injured patients. He has published over 150 peer reviewed papers, many in the most prestigious journal in the world. He is frequently invited to lecture at major international conferences.